abs192.txt	bcg	has	been	used	as	intravesical	immunotherapy	for	the	treatment	of	bladdercarcinoma		however		this	treatment	is	not	harmless	and	may	lead	to	complications	with	a	reported	incidence	of	systemic	bcg	infection	ranging	from	3%	to	7%		wereport	a	case	of	culture-proven	mycobacterium	bovis	(bcg)	vertebral	osteomyelitisin	a	72-year-old	patient	with	bladder	carcinoma	who	was	treated	with	intravesicalmitomycin	c	but	did	not	receive	bcg		cultures	from	biopsy	recovered	isolateresembling	mycobacterium	tuberculosis	biochemically		but	resistant	topyrazinamide	(pza)		the	patient	was	originally	started	on	a	four-drugantituberculous	regimen	of	isoniazid		rifampin		ethambutol	and	pza		aftergenotypic	analysis	identified	the	organism	as	m		bovis	(bcg)		the	regimen	waschanged	to	isoniazid	and	rifampin	for	12	months		the	patient	responded	well	tothis	treatment		this	case	is	unique	as	the	patient	received	only	intravesicalmitomycin	and	did	not	receive	bcg		implying	the	possibility	of	transmission	fromcontaminated	equipment	
